|
|
|
|
|
Targeted Oncology
Identification of EGFR Mutations Impacts Overall Prognosis in Lung Cancers
|
|
|
|
Brennan J. Decker, MD, PhD, a clinical fellow in the Department of Pathology at Brigham and Women’s Hospital in Boston, Massachusetts, discusses the role of identifying EGFR mutations in patients with lung cancers. In lung adenocarcinoma, there are many different activating mutations that can lead to the development of cancer, Decker explains.
Molecular mutations, such as the EGFR mutation, can be thought of like flipping a switch that activates cancer in some way. The major breakthrough in the treatment of patients with EGFR-positive lung cancer has been the development of osimertinib (Tagrisso) and other EGFR-targeted therapies, according to Decker.
The EGFR gene is a signaling molecule, and when this “switch” is turned ...
Read more
|
|
|
|
|
|
|
|
|
MedWireNews
FDA approves atezolizumab combination for metastatic NSCLC
|
|
|
|
medwireNews: US patients with stage IV, nonsquamous non-small-cell lung cancer (NSCLC) lacking EGFR or ALK alterations can now receive first-line treatment with atezolizumab plus nab-paclitaxel and carboplatin. The recommended dose of atezolizumab is 1200 mg every 3 weeks and the PD-L1 inhibitor should be given first if administered on the same day as chemotherapy. The FDA decision follows positive overall survival results from the IMpower130 trial favoring the addition of the PD-L1 inhibitor to the chemotherapeutic regimen.
Read more
|
|
|
|
|
|
|
|
|
Medical News Today
Wet and cold weather linked to increased cancer rates
|
|
|
|
For the first time, a study finds an association between living in cold, wet regions and increased cancer prevalence. The conclusions are surprising and likely to spark debate.
Long ago, scientists that increased exposure to ultraviolet (UV) rays from the sun increases skin cancer risk. A new study, however, points the finger at precipitation and a cooler climate.
Earlier research has shown that there is a surprising amount of disparity between cancer incidence and mortality rates in different regions of the United States.
Read more
|
|
|
|
|
|
|
|
|
BioSpace
After Five Potential Blockbuster Wins This Year, Novartis Sees 25 More on Its Horizon
|
|
|
|
Lucarista / Shutterstock
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
During an RD Day presentation, the Swiss pharma giant touted that it has the number one most valuable pipeline according to external rankings. The company has more than 500 ongoing clinical trials with 160 different projects in clinical development, 16 of which are advanced platform therapies.
Read more
|
|
|
|
|
|
|
|
|
BioSpace
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial
|
|
|
|
SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced the appointment of Ms. Shirley Zhao to the position of General Manager for Greater China and Head of Commercial. In this position, Ms. Zhao will be responsible for the commercialization of the Company's products and will report directly to Dr. Frank Jiang, Chairman and CEO of CStone.
Ms. Zhao is a seasoned industry leader with over 26 years of experience working at multiple multinational biopharmaceutical companies.
Read more
|
|
|
|
|
|
|
|
|
Cancer Network
Brendon M. Stiles, MD, Discusses Low-Dose Radiation Therapy Along with Immunotherapy
|
|
|
|
Brendon M. Stiles, MD, discussed NewYork-Presbyterian Hospital’s trial testing of low dose radiation therapy along with immunotherapy prior to taking out the tumors in a neoadjuvant setting at the Annual New York Lung Cancers Symposium®.
Transcription:
Well I think just being at the meeting today, you can see that there’s so many moving parts; everything is really exciting. We’ve never had more tools to deal with lung cancer. I love the combination of all of these therapies. I think there’s a place to combine surgery with immunotherapy, I think surgery with targeted therapy, surgery with radiation therapy.
We at our institution have a trial where we give low dose radiation therapy along with immunotherapy prior to taking out the tumors ...
Read more
|
|
|
|
|
|
|
|
|
MedPageToday
AI Mines Lung Ca Screening CT Scan to Assess CAC
|
|
|
|
CHICAGO – An artificial intelligence (AI) algorithm offered an automated tool to measure coronary artery calcium (CAC) in patients undergoing low-dose CT lung cancer screening (LDCT LCS), researchers reported here.
The deep learning algorithm was developed in 1,600 cardiac CTs with manual CAC measurement as the reference. The deep learning calcium score was categorized as high (CAC >300), moderate (CAC 101-300), low (CAC 1-100), and very low (CAC 0), according to Roman Zeleznik, a PhD candidate at Brigham and Women's Hospital (BWH)/Dana-Farber Cancer Institute in Boston, and colleagues.
The association of the deep learning CAC score with all-cause and cardiovascular (CV) mortality was then tested in 14,959 heavy smokers (ages 55-74) under...
Read more
|
|
|
|
|
|
|
|
|
MedPageToday
Geography Explains Lung Surgery Disparities
|
|
|
|
New research confirms a wide variation in surgical rates for early-stage lung cancer by county of residence in the U.S.
Living in counties with high poverty levels, low levels of health insurance, and low access to healthcare delivery were all associated with lower rates of potentially curative surgeries among patients with early-stage non-small cell lung cancer (NSCLC) in a study conducted by researchers from the American Cancer Society (ACS) and Baptist Cancer Center in Memphis.
A more than two-fold between-county difference was seen in surgical rates among counties with the lowest and highest percentage of surgeries, ACS investigator Helmneh Sineshaw, MD, told MedPage Today.
As shown in the study online in CHEST, surgery prevalence fo...
Read more
|
|
|
|
|
|
|
|
|
South China Morning Post
Study finds male birth control drug may hold promise for lung cancer
|
|
|
|
A compound derived from cotton seed could be effective in treating lung cancer, according to a Chinese study. Photo: Shutterstock
Read more
|
|
|
|
|
|
|
|
|
ABC News
Texas IDs cancer cluster in polluted Houston neighborhood
|
|
|
|
Texas health officials identified a cancer cluster in a north Houston neighborhood polluted by the wood preservative creosote from a nearby railroad operation, prompting calls from residents and the city for a more in-depth investigation of potential ongoing risks.
An assessment by the Department of State Health Services didn't attempt to determine whether the cancers were linked to chemicals beneath homes in the city's Fifth Ward and Kashmere Gardens. But the Texas Commission on Environmental Quality requested the assessment because of residents' concerns that a plume of polluted groundwater from the Union Pacific site had made some of them sick, and city health officials said it underscored the need for a closer examination.
”I was cryi...
Read more
|
|
|
|
|
|
|
|
|
New York Times
Opinion | No One Should Have to Breathe These Chemicals
|
|
|
|
Two months later, the Trump administration blocked the regulations from taking effect, and now the E.P.A. has released a final rule that eviscerates the Obama-era requirements. The agency rescinded major accident prevention provisions, including requirements to consider safer technology, audits of accidents by outside parties and “root cause” analyses of accidents.
While Texas has the largest number of chemical facilities in the country, Illinois, California, Iowa and Louisiana are riddled with them, too.
Read more
|
|
|
|
|
|
|
|
|
Springer
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
|
|
|
|
Cancer treatment using immune checkpoint inhibitors is widely used, although biomarkers predictive of response are not well established. However, both the expressions of programmed cell death ligand 1 (PD-L1) and the tumor mutation burden (TMB) hold promise as such biomarkers for immune checkpoint inhibitors; however, its characteristics and clinical and immunological impacts have not been fully analyzed. We, therefore, evaluated the clinical and immunological parameters related to TMB to identify potential new biomarkers.
Read more
|
|
|
|
|
|
|
|
|
Nature
Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution
|
|
|
|
To identify EMT states in lung cancer cells, we used TGFβ for EMT induction. First, we examined TGFβ responsiveness in three non-small-cell lung carcinoma (NSCLC) cell lines (HCC827, A549, H3255) towards bulk expression of widely accepted EMT markers (E-Cadherin, Vimentin, CD442,4,17) (Fig. 1a). A549 cells displayed partial EMT (pEMT) characteristics before TGFβ treatment (basal co-expression of epithelial (E-Cadherin) and mesenchymal (Vimentin, CD44) markers). With treatment, A549 cells exhibited loss of E-Cadherin and acquired mesenchymal-like morphology (Fig. 1a, Supplementary Fig. 1).
Read more
|
|
|
|
|
|
|
|
|
Nature
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
|
|
|
|
Increased glucose metabolism in cancer results in different steady-state concentrations of metabolites in tumors relative to normal tissues, which can have implications for cell signaling, bioenergetics, and the availability of substrates that support biosynthesis and cell proliferation10,11. To identify metabolites that differentially accumulate in lung cancers relative to normal lung tissue, we performed untargeted LCMS-based metabolomics on normal lung and lung tumor tissue derived from two autochthonous mouse models of KrasG12D-driven NSCLC that have been shown to avidly consume glucose12,13,14.
Read more
|
|
|
|
|
|
|
|
|
Springer
Ovarian cancer stem cells and targeted therapy
|
|
|
|
The prognosis of ovarian cancer is directly related to the stage of tumor and tumor cells remaining after resection. Exploratory laparotomy paves the way for tumor staging and debulking [19]. Having command on the spread pattern of ovarian cancer is highly required in appropriate radiological determining, diagnosis, and surgery [20]. Computed tomography (CT) is used for ovarian cancer staging before the surgery and also for the determination of tumor relapse [21]. MRI and multi detector CT are efficient methods for ovarian cancer staging [19].
Read more
|
|
|
|
|
|
|
|
|
Nature
Biochemistry | Nature Communications
|
|
|
|
Glycolysis is elevated in many cancers. In this study, the authors show that lactoylglutathione, a by-product of methylglyoxal produced from increased glycolysis, is elevated in lung cancer in mouse models and humans, arguing reactive metabolite production can be a liability for cancers.
Read more
|
|
|
|
|
|
|
|
|
Nature
Cancer | Nature Communications
|
|
|
|
Glycolysis is elevated in many cancers. In this study, the authors show that lactoylglutathione, a by-product of methylglyoxal produced from increased glycolysis, is elevated in lung cancer in mouse models and humans, arguing reactive metabolite production can be a liability for cancers.
Read more
|
|
|
|
|
|
|
|
|
Nature
An aggressive cancer’s road to conquest
|
|
|
|
The type of cell that gives rise to a tumour can also dictate the tumour’s evolutionary path — and the mechanism by which it spreads through the body, studies in mice suggest.
Small-cell lung cancer is one of the most lethal cancers, and among those most likely to spread, or metastasize. Monte Winslow and Julien Sage at the Stanford University School of Medicine in California and their colleagues studied small-cell lung cancer in two different mouse models of the disease. In one model, genetic changes that lead to cancer occurred only in a subset of lung cells called neuroendocrine cells.
Read more
|
|
|
|
|
|
|
|
|
PubMed
A typical carcinoid of the lung - a case report with pathological correlation and propagation of the cancer stem cell line BKZ1 with synaptophysin ... - PubMed - NCBI
|
|
|
|
Neuroendocrine tumors (NETs) of the lung account for 5% of all cases of lung cancer, which itself is the leading cause of cancer-related death worldwide. In accordance to its rarity, only few cell lines of NETs exist, which even often lack key characteristics of the primary tumor, making it difficult to study underlying molecular mechanisms.
The patient reported in this case is a 71-year old woman, which never smoked but suffered under dry cough.
Chest CT-scan showed a paracardiac nodule of the lingula with 2 × 1.8 cm in diameter.
The detected paracardiac nodule of the lingula was anatomically resected using video assisted thoracic surgery.
Histopathological diagnostic of the removed tissue identified the tumor as a well-differentiated ...
Read more
|
|
|
|
|
|
|
|
|
PubMed
Co-existence of well-differentiated fetal adenocarcinoma of the lung with tuberculosis in a young female: A rare case report. - PubMed - NCBI
|
|
|
|
Fetal adenocarcinoma of the lung (FLAC) with fetal lung-like morphology is a rare entity of pulmonary adenocarcinoma. Well-differentiated fetal adenocarcinoma (WDFA) belongs to its the low-grade form, which possesses a relatively favorable prognosis. Tuberculosis (TB) is an aggressive infectious disease that has been ranked as one of the top 10 causes of death worldwide. There may be a connection between the 2 and attention should be paid to the differential diagnosis.
A 28-year-old non-smoking female was admitted with signs of hemoptysis, and she had been coughing up phlegm for 5 years.
Read more
|
|
|
|
|
|
|
|
|
European Society for Medical Oncology
Cervical Cancer Ranked in the Top Three Cancers Affecting Women | ESMO
|
|
|
|
Results from the study published online on 4 December 2019 in The Lancet Global Health provide updated estimates of the cervical cancer burden 10 years after the 2008 GLOBOCAN publication1. In particular, cervical cancer remained a major public health problem, ranking in 2018 as the fourth most common cause of cancer incidence and mortality in women worldwide. Ten years ago, cervical cancer ranked as the third most common cancer among women worldwide, but in 42 low-resource countries, it was the most common cancer in women.
In 2018, the study team observed a significant positive correlation between national age-standardised incidence rate (ASIR) and corresponding estimates of human papillomavirus (HPV) prevalence.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Young Investigators awarded $200k to study how the body’s own defense mechanisms may be used in the fight against lung cancer
|
|
|
|
Lung Cancer Foundation of America, International Lung Cancer Foundation (ILC Foundation) fund two new Young Investigator grants focusing on immunotherapy
Los Angeles, CA, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Two new $200,000 grant-funded studies supported by the Lung Cancer Foundation of America, the International Lung Cancer Foundation, and generously funded in part by Bristol-Myers Squibb, are investigating the interaction between lung cancer immunotherapy and the microbiome. The microbiome is the environment of trillions of bacteria, fungi and other microbes that play a very important role in your health.
Read more
|
|
|
|
|
|
|
|
|
Seeking Alpha
Novartis developing 25+ blockbusters - R&D Day
|
|
|
|
At its R&D Day in London yesterday, Novartis (NYSE:NVS) detailed its development efforts. Key points:
25+ potential blockbusters in development, 16 advanced platform therapies and 160+ projects in the clinic (500+ clinical trials).
Key filings expected in 2020: alpelisib for PROS, AVSX-101 for SMA Type 2/3, Entresto for HFpEF, fevipiprant for asthma, 177Lu-PSMA-617 for mCRPC and spartalizumab combo for metastatic melanoma.
Over 50 filings expected in China through 2023.
Key emerging assets: iscalimab (CFZ533) in transplant, Sjögren’s syndrome; LNP023 in renal diseases and RA; MBG453 in myeloid disorders and TQJ230 for lowering CV risk.
Read more
|
|
|
|
|
|
|
|
|
This is Money
Texas IDs cancer cluster in polluted Houston neighborhood
|
|
|
|
HOUSTON (AP) - Texas health officials identified a cancer cluster in a north Houston neighborhood polluted by the wood preservative creosote from a nearby railroad operation, prompting calls from residents and the city for a more in-depth investigation of potential ongoing risks.
An assessment by the Department of State Health Services didn't attempt to determine whether the cancers were linked to chemicals beneath homes in the city's Fifth Ward and Kashmere Gardens. But the Texas Commission on Environmental Quality requested the assessment because of residents' concerns that a plume of polluted groundwater from the Union Pacific site had made some of them sick, and city health officials said it underscored the need for a closer examinatio...
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Global Airway Stent Market to 2024: Rising Prevalence of Several Respiratory Chronic Disorders Attributed to Growth
|
|
|
|
DUBLIN, Dec. 6, 2019 /PRNewswire/ -- The "Global Airway Stent Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
The global airway stent market is expected to reach $213.978 million by 2024 from $168.184 million in 2018 growing at a CAGR of 4.10%.
Airway stent or tracheobronchial prostheses are tube-shaped devices with a hollow lumen to relieve airway obstruction caused by strictures not suitable for resection and reconstruction. Recently, a variety of endoscopic techniques have been developed to manage benign and malignant lesions involving the central airway: mechanical debridement, laser resection and vaporization, photodynamic therapy, and endobronchial brachytherapy.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Global Airway Stent Market Report 2019: Market is Expected to Reach $213.978 Million by 2024 from $168.184 Million in 2018 - ResearchAndMarkets.com
|
|
|
|
The "Global Airway Stent Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
The global airway stent market is expected to reach $213.978 million by 2024 from $168.184 million in 2018 growing at a CAGR of 4.10%.
Airway stent or tracheobronchial prostheses are tube-shaped devices with a hollow lumen to relieve airway obstruction caused by strictures not suitable for resection and reconstruction. Recently, a variety of endoscopic techniques have been developed to manage benign and malignant lesions involving the central airway: mechanical debridement, laser resection and vaporization, photodynamic therapy, and endobronchial brachytherapy.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial
|
|
|
|
SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced the appointment of Ms. Shirley Zhao to the position of General Manager for Greater China and Head of Commercial. In this position, Ms. Zhao will be responsible for the commercialization of the Company's products and will report directly to Dr. Frank Jiang, Chairman and CEO of CStone.
Ms. Zhao is a seasoned industry leader with over 26 years of experience working at multiple multinational biopharmaceutical companies.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
|
|
|
|
This week, the FDA granted approval to Roche’s RHHBY cancer immunotherapy Tecentriq for expanded use in lung cancer. It also granted priority review status to AstraZeneca AZN & Merck’s MRK applications looking for label expansion approvals of their PD-L1 inhibitors Imfinzi and Keytruda, respectively. Meanwhile, J&J JNJ said that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirmed that the talc does not contain asbestos, a known carcinogen.
Recap of the Week’s Most Important Stories:
FDA Grants Priority Review to AstraZeneca & Merck’s Supplemental Applications: AstraZeneca’s supplemental biologics license application (sBLA) looking for approval of Imfinzi for the first-line treatment of extens...
Read more
|
|
|
|
|
|
|
|
|
Twitter
Medicine Matters oncology atezolizumab, NSCLC, LungCancer, Immunotherapy: 06/12/2019 17:10:11
|
|
|
|
approvalsWatch: @US_FDA approves first-line #atezolizumab plus nab-paclitaxel and carboplatin for patients with nonsquamous, metastatic #NSCLC lacking EGFR/ALK alterations. #LungCancer #Immunotherapy @HWestMD
Read more
|
|
|
|
|
|
|
|
|
Twitter
ecancer atezolizumab, NSCLC, Immunotherapy, Oncology, IMpower130: 06/12/2019 18:54:14
|
|
|
|
@US_FDA FDA approves #atezolizumab with nab-paclitaxel and carboplatin for metastatic #NSCLC without EGFR/ALK aberrations.
Read more here: https://t.co/rWoM8e8BXS
#Immunotherapy #Oncology #IMpower130
Read more
|
|
|
|
|
|
|
|
|
Twitter
The Oncologist : 06/12/2019 14:00:17
|
|
|
|
FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations
Read more
|
|
|
|
|
|
|
|
|
Twitter
Darcy Burbage, DNP, RN, AOCN : 06/12/2019 18:34:00
|
|
|
|
Men and Women May Respond Differently to Immunotherapy for NSCLC
Read more
|
|
|
|
|
|
|
|
|
Twitter
CNOR Nurses : 06/12/2019 21:02:15
|
|
|
|
Dr. Tina Cascone, MD, Ph.D., assistant professor of thoracic and head and neck cancer at The University of Texas MD Anderson Cancer Center discusses the remaining challenges with perioperative immunotherapy in non-small cell lung cancer (NSCLC).
https://t.co/cR35VGCq3Y
Read more
|
|
|
|
|
